摘要:
A method for producing an image of an object includes scanning an object with an imaging apparatus to collect projection data of the object utilizing cone sampling. The projection data is rebinned in a row-wise, fan-to-parallel fashion to produce rebinned data and the rebinned data is view-weighted to produce view-weighted data. The method further includes filtering the view-weighted data utilizing a row-wise ramp filter to produce filtered data and generating an image of the object utilizing the filtered data and a three-dimensional (3D) backprojection.
摘要:
A CT Fluoro system having an architecture and algorithms which facilitate increasing the frame rate and providing acceptable image quality is described. Generally, and in one embodiment, the system includes apparatus and algorithms that speed-up image reconstruction and reduce image artifacts that may result from such fast reconstruction. The fast reconstruction is achieved by performing, for example, view compression, channel compression, backprojection with reduced delay, and parallel processing.
摘要:
A system and method for analyzing and visualizing spectral CT data includes access of a set of image data acquired from a patient comprising spectral CT data, identification of a plurality of target regions of interest (TROIs) and a reference region of interest (RROI) from the set of image data, extraction of a plurality of target spectral Hounsfield unit (HU) curves from image data representing the plurality of TROIs, extraction of a reference spectral HU curve from image data representing the RROI, normalization of the plurality of target spectral HU curves with respect to the reference spectral HU curve, and display of the plurality of normalized target spectral HU curves.
摘要:
A system and method for analyzing and visualizing spectral CT data includes access of a set of image data acquired from a patient comprising spectral CT data, identification of a plurality of target regions of interest (TROIs) and a reference region of interest (RROI) from the set of image data, extraction of a plurality of target spectral Hounsfield unit (HU) curves from image data representing the plurality of TROIs, extraction of a reference spectral HU curve from image data representing the RROI, normalization of the plurality of target spectral HU curves with respect to the reference spectral HU curve, and display of the plurality of normalized target spectral HU curves.
摘要:
Systems, method and apparatus in which some implementations of respiratory structure imaging includes tracking a portion in a organ, determining wall contours in the portion and color-coding confidence in the wall contours. Some implementations of the color-coding includes selecting a cross section of a portion, determining average intensity of a wall in the organ from equally space ray vectors, determining confidence from a distribution of the average intensity, labeling sections of an organ image in reference to the average intensity, and color coding sections of the image in the memory according to the confidence.
摘要:
An imaging system includes a detector configured to receive data that can be reconstructed into a three-dimensional (3D) image of an object, and a computer programmed to obtain 3D image data of the object, the 3D image data including an internal structure of the object, define a longitudinal dimension of the internal structure from the 3D image data along a length of the structure, extract a first set of parameter-of-interest data related to the internal structure from the 3D image data along a first ray extending from a first location along the length of the structure and at a first angular orientation with respect to a base vector that is generally perpendicular to the longitudinal dimension, and plot the extracted first set of parameter-of-interest data at a pixel location of a two-dimensional (2D) plot that corresponds to the first location and corresponds to the first angular orientation.
摘要:
The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
摘要:
The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.
摘要:
A method for generating a score for soft plaque in coronary arteries includes using the computer to estimate the soft plaque content within at least one object depicted in a medical image, using the computer to determine a plaque score dependent upon the estimated soft plaque content of the at least one object, and using the computer to report the plaque score.
摘要:
A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.